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[57] ABSTRACT 
Prodrugs containing an active drug molecule linked to a 
polyethylene glycol group. and a method of use thereof are 
described. Exemplary soluble ester prodrugs contain 
naproxen. triamcinolone acetonide, gancyclovir. taxol. 
cyclosporin, dideoxyinosine, nihydroxy steroids. and ?ur 
biprofen molecules linked to polyethylene glycol (PEG) 
groups. Pharmaceutical compositions containing these 
prodrugs. and a method of using these esters for treating 
disease states or symptoms are also described. 
10 Claims, 6 Drawing Sheets 
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PERMEABLE, NON-IRRITATING 
PRODRUGS OF NONSTEROIDAL AND 
STEROIDAL AGENTS 
This application is a continuation in part application of 
Ser. No. 08/162388. ?led Dec. 7. 1993 abandoned upon 
?ling this application. which is a continuation of Ser. No. 
081016.179. ?led Feb. 11. 1993. now abandoned which is a 
continuation of Ser. No. 07/601.644. ?led Oct. 23. 1990. 
now abandoned 
TECHNICAL FIELD 
The present invention relates to non-steroidal or steroidal 
prodrugs and methods of use thereof. More particularly. the 
invention relates to soluble ester prodrugs of polyethylene 
glycol and naproxen. taxol. DDL gancyclovir. cyclosporin. 
triarncinolone acetonide. trihydroxy steroid prodrugs. or 
?urbiprofen prodrugs and a method of using these esters as. 
for example anti-inflammatory agents. antiviral agents. 
immunomodulating agents. and for the inhibition of 
neovascularization. etc.. as appropriate. 
BACKGROUND ART 
Steroidal compounds and non-steroidal compounds are 
known in the art and their utility is accepted by those of skill 
in the art and dosage ranges of these compounds are known. 
U.S. Pat. No. 4.786.495 to Bird discloses ?urbiprofen and 
salts thereof in admixture with an excipient encompassing 
fatty acid esters such as polyol esters of polyethylene glycol 
(see. column 1. line 42+ and claims 1 and 6). The Bird 
composition contains the drug and an excipient which is 
separate therefrom. No ester derivatives of the drug are 
disclosed. 
U.S. Pat. No. 4.767.751 to David discloses polyethylene 
glycol type solubilizers for ?urbiprofen (see. column 1. lines 
54-65 and column 3. line 36 of Davis). This reference 
provides a composition comprising two phases. one of 
which contains a drug. No ester derivatives of the drug is 
mentioned. 
U.S. Pat. No. 4.613.505 to Mizushima discloses esters of 
?urbiprofen which are different from those of the present 
invention (see. R in the chemical structure appearing in the 
abstract and claim 1). The ?urbiprofen ester is dissolved in 
a vegetable oil and emulsi?ed. For human beings the com 
position may also comprise a nonionic surface active agent 
such as polyalkylene glycol and copolymers thereof (see. 
column 4. lines 22-38 of Mizushima). 
U.S. Pat. No. 4.489.080 to Lomen discloses alkyl esters of 
?urbiprofen (see. Example 6 of Lomen). U.S. Pat. No. 
4.443.476 to Lomen also relates to alkyl esters of ?urbipro 
fen (see. column 1. lines 34-50 of Lomen). The compounds 
are disclosed in both patents as being useful for the treatment 
of adult respiratory distress syndrome and are administered 
systematically. 
U.S. Pat. N o. 4.477.468 to Heckler discloses the systemic 
administration and topical application of ?urbiprofen. salts 
thereof and esters thereof. The esters are (C1-C8) alkyl 
esters and are prescribed for the prophylactic and therapeutic 
treatment of herpes type II virus. U.S. Pat. Nos. 4.473.584. 
4.443.476 and 4.439.451 are related to U.S. Pat. No. 4.477. 
468. 
U.S. Pat. No. 4.412.994 to Sloan discloses hydroxamic 
derivatives of ?urbiprofen as prodrugs (see. chemical struc 
ture appearing in column 2. lines 10-20 and column e. line 
32 of Sloan). No esters are disclosed in this patent. U.S. Pat. 
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No. 4.206.220 relates to compounds that are similar to those 
of U.S. Pat. No. 4.412.994. These compounds are aminoxy 
derivatives of. e.g.. ?urbiprofen (see. structure shown in the 
abstract). 
U.S. Pat. No. 4.009.283 to Herr et al discloses alkyl esters 
of ?urbiprofen (see. the chemical structure shown in the 
abstract). The esters are lower alkyl esters. 
Canadian Patent CA 1.148.165 and German Patent DE 
3.811.118 disclose esters of ?urbiprofen. 
It has been recognized in the art that the anti 
in?ammatory agent. ?urbiprofen. produces local irritation 
when applied for treatment of in?ammation. Various tech 
niques have been used to try to lower the dosage of ?urbi 
profen to the patient. such as techniques for rapid release of 
the ?urbiprofen into the body. 
Accordingly. there has been a long standing need in the art 
for compositions having the effect of ?urbiprofen which 
avoid or reduce the local irritation brought about as com 
pared to ?urbiprofen. This is particularly true in the appli 
cation of the ?urbiprofen anti-in?ammatory agent to the eye. 
Surprisingly. certain compounds including prodrugs of poly 
ethylene glycol (PEG) and naproxen. triamcinolone 
acetonide. or trihydroxy steroid prodrugs. gancyclovir. 
cyclosporin. taxol. DB1 and ?urbiprofen prodrugs have now 
been discovered which show signi?cant therapeutic proper 
ties and bioavailability. 
SUMMARY OF THE INVENTION 
An object of the invention is to provide a prodrug com 
prising a steroidal or non-steroidal compound linked to a 
polyethylene glycol of the formula: HO(CH2CH2O)nH. 
wherein n=2-12. In a preferred embodiment n=3—6 or 2-6. 
Non-steroidal compounds such as indomethacin or 
naproxen are preferred Steroidal compounds selected from 
the group consisting of triamcinolone acetonide. and nihy 
droxysteroid are also preferred. Other antiviral compounds 
such as gancyclovir. irnmunomodulating agents such as 
cyclosporin. and anti-tumor agents such as taxol. etc.. may 
also be linked to polyethylene glycol to increase their 
bioavailability. 
In an alternative embodiment the steroidal. non-steroidal 
or other compound is linked to polyethylene glycol by a 
carbonate link. 
A further object of the present invention is to provide a 
compound having the anti-in?ammatory effect of ?urbipro 
fen which either avoids or reduces the local irritation 
brought about as compared to ?urbiprofen. Also provided 
are other steroidal and non-steroidal prodrugs. 
Another object of the present invention is to provide a 
pharmaceutical composition comprising a compound having 
the anti-inflammatory effects. for example. of ?urbiprofen 
which avoids or reduces the local irritation brought about as 
compared to ?urbiprofen. 
A still further object of the present invention is to provide 
an improved method for treating in?ammation or other 
disease condition. in a non-human mammal or a human 
being which comprises the administration of an e?ective 
amount of a compound according to the invention or a 
pharmaceutical composition comprising an effective amount 
of a compound according to the invention. which has the 
anti-in?ammatory effects or other disease or symptom 
reducing elfects of ?urbiprofen or other compound of the 
invention. to treat disease conditions or symptoms. as appro 
priate. 
Also the invention provides for prodrugs of PEG and 
naproxen. triamcinolone acetonide. or tn'hydroxy steroidal 
5,681,964 
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drugs. The solubility of ?urbiprofen can be decreased and 
lipophilicity increased. when the molecule is conjugated to 
two PEG molecules instead of one PEG molecule. The 
prodrugs of the invention have enhanced transdermal 
absorption. for example by partitioning into the stratum 
corneum and remaining there until enzymatically cleaved. 
In the alternative the solubility of poorly soluble steroids. 
such as triamcinolone acetonide can be greatly increased by 
conjugation to polyethylene glycol (PEG). 
Solubility of the steroidal molecules can be adjusted by 
altering the length of the PEG chain. as can the half-life of 
the molecule in the body. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shows the structure of PEG derivatives of 
indomethacin. 
FIG. 2 shows the structure of PEG derivatives of 
naproxen. 
FIG. 3 shows the structure of PEG derivatives of conju 
gates of triamcinolone acetonide. 
FIGS. 4A-4C show the structure of PEG derivatives of 
trihydroxysteroid. 
DESCRIPTION OF INVENTION 
The invention relates to soluble ester prodrugs of poly 
ethylene glycol and naproxen. triamcinolone acetonide. 
trihydroxysteroid. gancyclovir. cyclosporin. taxol. DDI 
prodrugs. and ?urbiprofen prodrugs. In accordance with this 
invention there are disclosed compounds of the formula: 
wherein R1. R2. R3 and R4 are selected from the group 
consisting of H. C1—C4-alkyl and C1—C4-hydroxalkyl and n 
is a number from 2 to 12. inclusive. and R is selected from 
the group consisting of H. C1-C4 alkyl. C1-C4 hydroxalkyl 
and a group having the formula: 
0 
ll 
including isomeric forms and pharrnaceutically acceptable 
salts. Pharmaceutically acceptable salts can be. for example. 
the alkali metal. alkali earth and ammonium salts. 
Preferred are compounds according to Formula I wherein 
R1. R2. R3 and R, are hydrogen and n is a number from 2-8 
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and R is H or a group having the formula H. Even more 
preferred are compounds according to Formula I wherein 
R1. R2. R3 and R4 are hydrogen and n is 4 or 6 and R is 
hydrogen or a group having the formula II. 
The compounds of Formula I have an asymmetric carbon 
atom and can exist as optical isomers. For the purpose of this 
invention. the racemic mixtures and the dextro and levo 
forms are included within the present invention. The racemic 
mixtures and the dextro forms are preferred. 
Further. the compounds of the present invention are useful 
in pharmaceutical compositions for systemic administration 
to humans and animals in unit dosage forms. such as tablets. 
capsules. pills. powders. granules. suppositories. sterile 
parenteral solutions or suspensions. sterile non-parenteral 
solutions or suspensions oral solutions or suspensions. oil in 
water or water in oil emulsions and the like. containing 
suitable quantities of an active ingredient. Topical applica 
tion can be in the form of ointrnents. creams. lotions. jellies. 
sprays. douches. and the like. For oral administration either 
solid or ?uid unit dosage forms can be prepared with the 
compounds of Formula I. The compounds are useful in 
pharmaceutical compositions (wt %) of the active ingredient 
with a carrier or vehicle in the composition in about 1 to 20% 
and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example. the com 
pounds of Formula I can be mixed with conventional 
ingredients such as dicalciumphosphate. magnesium alumi 
num silicate. magnesium stearate. calcium sulfate. starch. 
talc. lactose. acacia. methyl cellulose and functionally simi 
lar materials as phannaceutical excipients or carriers. A 
sustained release formulation may optionally be used. Cap 
sules may be formulated by mixing the compound with a 
pharmaceutical diluent which is inert and inserting this 
mixture into a hard gelatin capsule having the appropriate 
size. If soft capsules are desired a slurry of the compound 
with an acceptable vegetable. light petroleum. or other inert 
oil can be encapsulated by machine into a gelatin capsule. 
Suspensions. syrups and elixers may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. A vegetable 
oil such as corn oil. peanut oil or sa?lower oil. for example. 
together with ?avoring agents. sweeteners and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to water to form a syrup for ?uid unit 
dosages. Hydroalcoholic pharmaceutical preparations may 
be used having an acceptable sweetener such as sugar. 
saccharine or a biological sweetener and a ?avoring agent in 
the form of an elixir. 
Pharmaceutical compositions for parenteral and supposi 
tory administration can also be obtained using techniques 
standard in the art. 
A preferred use of the compounds according to the 
invention is as topical anti-in?ammatory agents. as 
appropriate. suitable for application to either the eyes or the 
ears. Another preferred use of the compounds is in a 
transdermal parenteral anti-in?ammatory pharmaceutical 
preparation. which is particularly useful in the treatment of 
in?amed connective tissue in a mammal such as a human. 
Accordingly. compositions suitable for administration to 
these areas are particularly included within the invention. 
The above parenteral solutions or suspensions may be 
administered transdermally and. if desired a more concen 
trated slow release form may be administered. Accordingly. 
incorporation of the active compounds in a slow release 
matrix may be implemented for administering transder 
mally. The compounds may be administered transderrnally 
at about 1 to 20% of the composition and preferably about 
5 to 15% wt % of the active ingredient in the vehicle or 
carrier. 
5,681,964 
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Transdermal therapeutic systems are self-contained dos 
age forrns that. when applied to intact skin. deliver drug(s) 
at a controlled rate to the systemic circulation. Advantages 
of using the transdermal routing include: enhanced thera 
peutic e?icacy. reduction in the frequency of dosing. reduc 
tion of side effects due to optimization of the blood 
concentration versus time pro?le. increased patient 
compliance due to elimination of multiple dosing schedules, 
bypassing the hepatic “?rst-pass” metabolism. avoiding 
gastrointestinal incompatibilities and providing a predict 
able and extended duration of activity. However. the main 
function of the skin is to act as a barrier to entering 
compounds. As a consequence. transdermal therapy has so 
far been restricted to a limited number of drugs that possess 
the desirable physiochemical properties for di?’usion across 
the skin barrier. One effective method of overcoming the 
barrier function of the skin is to include a penetration 
enhancer in the formulation of a transderrnal therapeutic 
system. See Barry. Brian W.: Demratological Formulations: 
Percutaneous Absorption (Dekker. New York. 1983); 
Bronough et al. Percutaneous Absorption, Mechanisms— 
Methodology-Drug Delivery. (Marcel Dekker. New York. 
NY. 1985); and Monkhouse et al. Transdermal drug deliver 
problems and promises. Drug Dev. Ind. Pharm., 14. 
183-209 (1988). 
A penetration enhancer is a chemical compound that. 
when included in a formulation. temporarily increases the 
permeability of the skin to a drug allowing more of the drug 
to be absorbed in a shorter period of time. Several different 
types of penetration enhancers have been reported such as 
dimethylsulfoxide. n-decyl methyl sulfoxide. N.N 
dimethylacetamide. N.Ni-dimethylformamide. 
1-dodecylazacycloheptan-2-one (Azone). propylene glycol. 
ethanol. pyrrolidones such as N-methyl-2-pyrrrolidone 
(NMP) and surfactants. See Bronough et al. supra. and 
Stoughton et al. Azone: a New Non-toxic enhancer of 
percutaneous penetration. Drug Dev. Inc. Pharm, 9. 
725-744 (1983). 
N-methyl-Z-pyrrolidone is a versatile solvent which is 
miscible with water. ethyl alcohol. ether. chloroform. 
benzene. ethyl acetate and carbon disul?de. 
N-methylpyrrolidone has been Widely used as a solvent in 
industrial processes such as petroleum re?ning. GAF Corp.: 
“M-Pyrol (N-methyl-Z-pyrrolidone) Handbook”. GAF 
Corp.. New York. 1972. It is currently used as a solubilizing 
agent in topical and parenteral veterinary pharmaceuticals 
and is now under consideration for use in products intended 
for humans. Wells. D. A. et a1: Disposition and Metabolism 
of Double-Labeled [3H and mC] N-methyl-Z-pyrrolidone in 
the Rat. Drug Met. Disps., 16. 243-249 (1988). Animal and 
human experiments have shown very little irritation or 
sensitization potential. Ames type assays and chronic expo 
sure studies have not revealed any signi?cant toxicity. Wells 
et al. Mutagenicity and Cytotoxicity of N-methyl-2 
pyrrolidone and 4-(methyl amino) Butanoic Acid in the 
Salmonella/microsome Assay. J. Appl. Tore, 8. 135-139 
(1988). N -methylpyrrolidone has also been shown to be an 
effective penetration enhancer. Barry et al. Optimization and 
Bioavailability of Topical Steroids: Penetration Enhancers 
Under Occlusion. J. Inv. Derm., 82. 49-52 (1984); Akter et 
al. Absorption Through human Skin of Ibuprofen and Flur 
biprofen; Effect of Dose Variation. Deposited Drug Films. 
Occlusion and the Penetration Enhancer N-methyl-2 
pyrrolidone. J. Pharm. PharmacoL, 37. 27-37 (1984);Ho1e 
gaard et al. Vesical Etfect on Topical Drug Delivery IV. 
Effect of N-methylpyrrolidone and Polar Lipids on Percu 
taneous Transport. Int. J. Pharm, 43. 233-240 (1988); 
6 
Sugibayashi et al. Effect of Several Penetration Enhancers 
on the Percutaneous Absorption of Indomethacin in Hairless 
Rat. Chem Pharm. BulL, 36. 1519-1529 (1988); Bennett et 
a1. Optimization of Bioavailability of Topical Steroids: Non 
5 occluded penetration Enhancers Under Thermodynamic 
Control. J. Pharm. PharmacoL, 37. 298-304 (1985); Sasaki 
et al. Enhancing E?ect of Pyrrolidone Derivatives on Trans 
dermal Drug Delivery. 1. ing. J. Phdl'?L, 44. 14-24 (1988); 
lee et al. Toxicity of N-methyl-Z-pyrrolidone (NMP): 
Tetratogenic. Subchronic and Two-year Inhalation Studies. 
Fund. AppL, Tore, 9. 222-235 (1987). 
The above and other drugs can be present in the reservoir 
alone or in combination form with pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art known carriers that do not 
adversely a?'ect the drug. the host. or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile water; saline. dextrose; dextrose in water 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; lower alkanols; oils 
such as corn oil; peanut oil. sesame oil and the like. with 
emulsi?ers such as mono- or di-glyceride of a fatty acid. or 
a phosphatide. e.g.. lecithin. and the like; glycols; polyalky 
lene glycols; aqueous media in the presence of a suspending 
agent. for example. sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrolidone); and the like. alone. or with 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving stabilizing. wetting. emulsifying agents 
and the like together with the penetration enhancer of this 
invention. 
The etfective dosage for mammals may vary due to such 
factors as age. weight activity level or condition of the 
subject being treated. Typically. an effective dosage of a 
compound according to the present invention is about 10 to 
500 mg when administered by either oral or rectal dose from 
1 to 3 times daily. This is about 0.2 to about 35 mg per 
kilogram of the subject’s weight administered per day. 
Preferably about 20 to about 175 mg are administered orally 
or rectally l to 3 times a day for an adult human. The 
required dose is considerably less when administered 
parenterally. preferably about 10 to about 60 mg may be 
administered intramuscularly or transdermally. 1 or 2 times 
a day for an adult human. 
Compounds of the present invention may be administered 
topically at about 1 to 20 wt % of the composition. and 
preferably about 5 to 15 wt %. 
The reduced cornea damage by polyethylene glycol ?in 
biprofenate and bis-?urbiprofenate prodrugs in albino rabbit 
eyes was assessed by diiferential scanning calorimetry. Tests 
were conducted to investigate the effects of ?urbiprofen and 
the polyethylene glycol ?urbiprofen ester and the diester 
prodrugs on the cornea epithelium. The tests demonstrate 
that surprisingly. the soluble ester prodrugs reduce the local 
irritation which is observed in the treatment of ?urbiprofen 
which is not esteri?ed. that is ?urbiprofen which is in the 
free acid form. The effects of these drugs on the molecular 
structure of the cornea epithelium were assessed by differ 
ential scanning calorimetry. Fresh enucleated albino rabbit 
eyes were treated in solutions and also in suspensions of 
?urbiprofen and also in solutions and suspensions of the 
polyethylene glycol esters and diesters of ?urbiprofen in 
isotonic glutathione bu?’ered ringer solution for 10 minutes. 
The cornea epithelium was then scraped from the corneas 
and immediately analyzed by diiferential scanning calorim 
etry over the range of 40°—1 10° C. 
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Whenever a normal rabbit’s cornea epithelium was ana 
lyzed a large endothermic transition at 64°+ ° C. was 
observed. It has been established by previous work that this 
particular peak which was observed was due to a 
lipid\protein phase transition. It can be readily demonstrated 
that compounds which are known to damage the cornea. for 
example benzalkonium chloride greatly reduce the intensity 
of this observed peak. 
When the albino rabbit eyes were treated with a saturated 
solution of ?urbiprofen the cornea epithelium showed no 
phase transitions which indicates a substantially total break 
down of the normal protein/lipid structure. A reduced phase 
transition was found in corneas which had been treated with 
a 0.025% ?urbiprofen. Observing this data is consistent with 
reports that ?urbiprofen impairs cornea barrier function in 
vitro and is found to be irritating in man. 
Surprisingly. the cornea epithelium which is taken from 
albino rabbit eyes which have been treated with a saturated 
solution of the polyethylene glycol bis-?urbiprofenate 
showed only a marginal decrease in the exothermic transi 
tion when assessed by the di?’erential scanning calorimetry. 
Accordingly. this suggests a signi?cant reduction in the 
topical toxicity of the prodrugs according to the invention as 
compared to the ?urbiprofen. Additional tests. to assess the 
irritancy of the polyethylene glycol ?urbiprofenate and 
polyethylene glycol bis-?urbiprofenate. con?rm that there is 
a signi?cant reduction of the irritancy of the prodrugs 
according to the invention as compared to the ?urbiprofen 
acid form. 
Tests were conducted to determine that the polyethylene 
glycol ?urbiprofenates were prodrugs. that during transport 
across the cornea the polyethylene ?urbiprofenates are sub 
stantially converted to ?urbiprofen. 
Prepared was a 5% solution of an ester according to the 
present invention in glucathione buffered ringers solution. 
(approximately equivalent to a 1-3% ?urbiprofen solution). 
Human corneas were prepared and the experiment was run 
for 210 minutes. After 210 minutes the corneas remained 
clear. indicating a low degree of irritability. Little prodrug 
penetrated the receptor side. nearly all was converted to the 
?urbiprofen acid form during transport. This experiment 
was repeated using albino rabbit corneas mounted chambers. 
Samples were taken every 30 minutes for 210 minutes which 
were assayed by HPLC (high pressured liquid 
chromatography). The corneas appeared clear. hydration 
was determined to be about 80%. Even though the perme 
ation was rapid no ester was found on the receptor side since 
the ?urbiprofen acid form was produced during transport. 
Another experiment was performed with tetraethylene 
glycol ?urbiprofenate and tetraethylene glycol bis 
?urbiprofenate to determine the irritancy of these prodrugs 
in the rabbit eye. 
25 microliters of tetraethylene ?urbiprofenate were 
dropped into each eye of two rabbits each day for seven 
days. Also. 30 microliters of tetraethylene glycol bis 
?urbiprofenate was dropped into each eye of two rabbits 
each day for 7 days. A control using 25 microliters of 
?urbiprofen was dropped into each eye of two rabbits for 
seven days. Each morning the rabbit's eyes were examined 
by slit lamp for evidence of cornea damage and irritation. 
After seven days the animals were sacri?ced and samples of 
the aqueous humor and vitreous humor were obtained for 
analysis of ?urbiprofen and a ?urbiprofen ester. The eyes 
were also examined by electron microscopy. The ?urbipro 
fenates were converted into the ?urbiprofen acid form 
during transport into the eye. The degree of irritation to the 
cornea was signi?cantly reduced by use of the prodrug as 
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compared to ?urbiprofen in the acid form. The test was 
repeated using 10 microliters of each of the substances each 
day for seven days with similar results. 
Accordingly. these compounds are potent anti 
in?ammatory agents. By maintaining the activity of the 
?urbiprofen and having a low degree of imitation to the 
subject when administered. signi?cant advancements in the 
art of treating in?ammation have been accomplished. Such 
surprising results were not expected. 
The compounds of the invention can be prepared by 
conventional acid catalyzed or base catalyzed esteri?cation 
procedures known to the art. For example. the ?urbiprofen 
acid form can be reacted with the alcohol in the presence of 
an acid or base esteri?cation catalyst to produce the ?nal 
product esters according to the present invention. 
The following speci?c examples of this invention are not 
intended to limit the invention disclosed. Based upon the 
above disclosure and the following examples. other varia 
tions and permutations on the present invention will be 
apparent to one of ordinary skill in the art. 
Preparation of Compound according to Formula L 
EXAMPLE 1 
Tetraethylene glycol 2-(-Fluoro-4 biphenylyl)propionate 
and Tetraethylene glycol bis-2-(2-?uoro-4-biphenylyl) 
propionate. 
A mixture of 4 grams (0.0041 moles) of ?urbiprofen 
(2(2-?uoro-4-biphenylyl)propionic acid) and 30 ml of 
PEG200 (polyethylene glycol. i.e. tetraethylene glycol) 
(0.169 moles) and 4.2 ml of BF3-etherate (0.0328 moles) 
were re?uxed for 48 hours in 180 ml of acetonitrile. TLC 
(thin layer chromatography) indicated that the reaction had 
essentially reached completion in 12 hours. Following in 
vacuo removal of acetonitrile. a yellow-gold oily solution 
resulted. A sample of this product was subjected to TLC 
analysis on 60 angstroms silica gel plates 250 micrometers 
thick with F254 indicator; using ethyl acetate as the eluting 
solvent. Following development. the plates were dried under 
hot air and then read using a 254 nanometer UV lamp and 
iodine vapor. Compounds having ?urbiprofen derivatives 
show up under the ultraviolet light while PEG200 deriva 
tives show up on the presence of iodine vapor as a yellow 
spot. The impurities and excess PEG2°D with separated from 
the product to yield spots on the plate which are both UV and 
iodine vapor active thereby indicating that the esteri?cation 
reaction has been successful. The remaining product was 
then separated from the excess tetraethylene glycol by 
eluting the solution down a 4 centimeter><60 centimeter glass 
column packed with 60 angstrom silica gel/ethyl acetate 
slurry. About 4 grams of product (greenish oil) was obtained 
by the ?rst elution (the ?ow rate of eluant (ethyl acetate) was 
about 5 ml per minute). A second elution was performed to 
resolve the ?urbiprofen ester from the impurities and to 
separate the monoester from the diester by the di?‘erence in 
?ow rate. The monoester was eluted as the fourth fraction in 
the second elution. Yielded was about 1 gram of tetraethyl 
ene glycol 2-(2-tluoro-4-biphenylyl)propionate of product 
and about 1.5 grams of tetraethylene glycol bis-2-(2-?uoro 
4-biphenylyl)propionate of product. The structures were 
characterized by infrared spectra which con?rm the struc 
tures. 
5.681.964 
Assessment Signal (amt) 
1R Data of 'Ibtraethylene Glycol 
Flurbiprofenate (Monoester) 
3460 (broad —OH 
3020, 3060 (weak) aromatic C—H 
2940, 2860 (broad) aliphatic C—H 
1730 (strong) C=O (ester) 
1620 (weak) C=C (aromatic) 
1240 (broad C—O (ester) 
1120 C——O (ester) 
1R Data of 'Ibtraethylenc Glycol 
bis-Flurbiprofenate (Diester) 
3020, 3060 (weak) aromatic C—H 
2940, 2860 (broad) aliphatic C—H 
1730 (strong) C=O (ester) 
1620 (weak) C=C (aromatic) 
1240 (broad C—-C (ester) 
1120 C—O (ester) 
EXAMPLE 2 
Hexaethylene Glycol Fluriprofenate 
To 1 g (0.0041 moles) ?urbiprofen and 20 mL (0.07 
moles) PEG300 (hexaethylene glycol) in 150 mL of ACN 
were added 1.01 mlles BF3 etherate (as catalyst). This 
solution was re?uxed for about 25 hours. The solvent was 
removed in vacuo. The product was puri?ed in a manner 
similar to the puri?cation of the esters of Example 1. above. 
Yielded were about V; gram of hexaethylene glycol ?urbi 
profenate and about Vs hexaethylene glycol bis 
?urbiprofenate. 
Assessment Signal (amt) 
IR Data of Tetmethylene Glycol 
Flurbiprofenate (Monoester) 
3460 (broad) -—OH 
3020, 3060 (weak) aromatic C——H 
2940. 2860 (broad) aliphatic C—H 
1730 (strong) C=O (ester) 
1620 (weak) C=C (aromatic) 
1240 (broad) C—O (ester) 
1120 C—O (ester) 
IR Data of Hexaethylene Glycol 
bis-Flurbiprofenate (Diester) 
3020, 3060 (weak) aromatic C—H 
2940, 2860 (broad) aliphatic C—H 
1730 (strong) C=O (ester) 
1620 (weak) C=C (aromatic) 
1240 (broad) C—O (ester) 
1120 C—O (ester) 
EXAIVIPLE 3 
Octaethylene glycol ?urbiprofenate and octaethylene glycol 
bis-?urbiprofenate 
To one gram of ?urbiprofen and about 30 mL of PEG,’o0 
(octaethylene glycol) in 150 mL of ACN were added to 1.01 
mL of BFa-etherage (as catalyst). This solution was re?uxed 
for about 12 hours. The work up was substantially as 
indicated in Example 1 above. Yrelded was about 1/2 gram of 
octaethylene glycol ?urbiprofenate. The structure was con 
?rmed by IR data. 
EXAMPLE 4 
NMR spectra were recorded on a Varian VXR-300 spec 
trometer. Chemical shifts are in ppm relative to internal 
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tetramethylsilane. Column chromatography was performed 
using Aldrich silica gel (200-400 mesh). All compounds 
showed satisfactory purity by TLC on Analtech silica gel GF 
plates. 
Prodrugs from the Reaction of Naproxen Acid Chloride with 
Polyethylene Glycols (PEG). HO(CH2CH2O)nH. n=2. 3. 4. 
6 
Esters of naproxen and various polyethylene glycols have 
been synthesized as shown in Scheme 1. The following 
procedure allows one to obtain and easily separate two 
prodrugs from one reaction. 
To a solution of an appropriate polyethylene glycol (1 
mmol) in anhydrous dichloromethane (10 mL) was added 
pyridine (1.4 eq.) and naproxen acid chloride (1 mmol). The 
mixture was stirred overnight at room temperature. then 
washed successively with a saturated solution of sodium 
bicarbonate. water and brine. The organic phase was dried 
over Na2SO4. evaporated to an oil and the reaction products 
separated as shown below: 
Compounds 1a and 2a; Naproxen synthesis: 
The residue was chromatographed initially with benzene 
acetone (20:1) up to benzenezacetone (9.1) to give ?rst the 
less polar diester of naproxen and diethylene glycol 2a (97 
mg. 18.3% ). and then monoester 1a (178 mg. 56%) as oils. 
2a‘H NMR (CDCL3) [3 1.55 (d. 6H. CHCH3). 3.44 (m. 4H. 
OCHQ). 3.82 (q.2H.C?CH3). 3.85 (s. 6H. OCHB). 4.09 (m. 
4H. coocnz). 7.02-7.71 (m. 12H. aromatic) ppm; 13c 
NMR (CDCL3) B 174.48 (C=O). 157.60 (C-6). 135.51 
(C-2). 133.64 (C-10). 129.20 (C-8). 128.84 (C-9). 129.09 
(04). 126.18 ((3-3). 125.95 (C-l). 118.96 (07). 105.52 
(05). 68.87 (COOQHZ). 63.82 (OCH;). 55.22(0CH3). 
45.27 (QHCH3). 18.48 (CHQH3) ppm. la‘H NMR (CDCL3) 
B 1.58 (d. 3H. CHC?a). 3.40 (m. 2H. CHZOH). 3.55(m. 2H. 
OCHz). 3.85 (q. 1H CECHB). 3.86 (s. 3H. OCHs). 4.21 (m. 
2H. COOCH2. 7.06-7.72 (m. 6H. aromatic) ppm; 13CNMR 
(CDCL3) B 174.48 (C=O). 157.41 (C-6). 135.31 (C-2). 
133.47 (010). 129.03 (C-8). 128.67 (C-9). 126.93 (C-4). 
125.99 (03). 125.77 (C-l). 118.82 (C-7). 105.33 (C-5). 
72.13 (COOQH2). 68.72. 63.66. 61.34 (BXOCHZ). 55.05 
(OCH3). 45.13 (CHCH3). 18.29 (CHQH3) ppm. 
Compounds lb and 2b; Naproxen synthesis 
The crude oil (284 mg) was separated by chromatography. 
The column bed was washed with initially benzenezacetone 
(15:1) up to benzenezacetone (9:1). Two fractions were 
collected: the diester of naproxen and trimethylene glycol 21) 
(112 mg. 19.5% yield) and monoester 1b (173 mg. 47.5% 
yield) as colorless oils. 2b 1H NMR (CDCL3) [i 1.60 (d. 6H. 
CHCE3). 3.35 (s. 4H. OCH2CHO2O). 3.55 (t. 4H. OCHZ). 
3.88 (q22H. C?CH3). 3.88 (s. 6H. OCH,). 4.02 (m, 4H. 
COOCH2). 7.12-7.71 (m. 12H. aromatic) ppm; 3CNMR 
(CDCL3) B 174.47 (C=C). 157.S0(C-6). 135.50 (C-2). 
133.55 (010). 129.14 (C-8). 128.77 (09). 126.99 (C-4). 
126.14 (C-3). 125.87 (C-l). 118.88 (C-7). 105.41 (C-5). 
70.26 (COOQHZ). 68.84 (OCH2). 63.80 (OCHZ). 55.15 
(OCH3). 45.21 (QHCHS). 18.45 (CHCH3) ppm. 1b 1H NMR 
(CDCL3) [3 1.58 (d2 3H. CHCHS). 2.62 (1H. OH). 3.41-3.72 
(In. 8H.CH2O). 3.90 (q. 1H. C?CHa). 3.91 (s. 3H. OCH3). 
4.22 (m. 2H. COOCHQ). 7.06-7.72 (m. 6H. aromatic) ppm; 
13C NMR (CDCL3) B 174.57 (C=C). 157.55 (C-6). 135.54 
(C-2). 133.62 (C-10). 129.20 (C-8). 128.84 (C-9). 127.05 
(C-4). 126.21 (C-3). 125.95 (C-l). 118.92 (C-7). 105.48 
(05). 72.36 (COOCH2). 70.43. 70.16. 68.96. 63.83. 61.62 
(SXOCHZ), 55.23 (OCH3). 45.25 (QHCH3). 18.45 (CH 
CH3) ppm 
Compounds 1c and 2c; Naproxen Synthesis. 
The oily residue (294 mg) was chromatographed using 
initially benzene:acetone (12:1) up to benzene :acetone (4:1) 
5.681.964 
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as a solvent system Two products were isolated: the diester 
of naproxen and tetraethylene glycol 2c (170 mg. 27.5% 
yield) and monoester lo (150 mg. 37% yield). (2c) 1H NMR 
(CDCL3) [3 1.55 (d. 6H. CHC?a). 7.07-7.72 (In. 12H. 
aromatic) ppm; 1C NMR (CDCL3) B 174.52 (C==O). 157.54 
(C-6). 135.54(C-2). 133.59 (C-10). 129.18 (C-8). 128.81 
(C-9). 127.02 (C-4). 126.18 (C-3). 125.89 (C-l). 118.88 
(C-7). 105.46 (C-5). 70.38. 70.36. 68.92. 63.87 (4><OCH2). 
55.20 (OCH3). 45.25 (_C_HCH3). 18.49 (CHQH3) ppm. (1c) 
1H NMR (CDCL3) [5 1.58 (d. 3H. CHCHQ. 2.75 (1H. OH). 
3.51-3.73 (m. 14H. CHZO). 3.88 (q. 1H. CHCH3). 3.90 (s. 
3H. OCH;.). 4.22 (m. 2H. COOCHZ). 7.08-7.72 (m. 6H. 
aromatic) ppm; 13c NMR (cDcr.3 [s 174.41(c=0). 157.45 
(C-6). 135.46(C-2). 133.51 (C-10). 129.09 (C-8). 128.75 
(09). 126.96 (C-4). 126.10 (CI-3). 125.81 (C-l). 118.79 
(C-7). 105.39 (C-5). 72.32 (COOQHQ). 70.37. 70.31. 70.27. 
70.11. 68.85. 63.80. 61.51 (7><OCH2). 55.11 (OCH3). 45.17 
(QHCH3). 18.37 (CHQH3) ppm. 
Compounds 1d and 2d; Naproxen Synthesis 
The crude oil ( 337 mg ) was separated by chromatogra 
phy. The column bed was washed with initially benzene:ac 
etone (9:1) up to benzenezacetone (2:1) to give ?rst the less 
polar diester of naproxen and hexaethylene glycol 2d (100 
mg. 14.2% yield) and then the monoester 1d (230mg. 46.7% 
yield) as oils. 2d 1H NNIR (CDCL3) B 1.57 (d. 6H. CHC 
113). 3.48. 3.55 (2s. 16H. OCHQ). 3.60 (t. 4H. OCH;). 
7.07-7.72 (m. 12H. aromatic) ppm; l3CNMR (CDCL3) B 
174.38 (C=O). 157.40 (C-6). 135.40 (C-2). 133.46 (C-10). 
129.05 (C-8). 128.70 (C-9). 126.89 (C-4). 126.06 (C-3). 
125.77 (C-l). 118.75 (C-7). 105.34 (C-5). 70.30. 70.29. 
70.28. 70.26. 68.80. 63.76 (IZXOCHZ). 55.08 (OCH,). 45.11 
(cncrg). 18.35 (cncilé) ppm. 1d l-INMR (CDCL3) a 1.58 
(d. 3H. CHCI_-13). 3.00 (s. 1H. OH). 3.46-3.75 (m. 22H. 
CH2O). 3.85 (q. 1H. CHCH3). 3.88 (s. 3H. OCH3). 4.22 (m. 
2H. COOCHZ). 7.08-7.73 (m. 6H. aromatic) ppm; 13C NMR 
[5 174.41 (C=O. 157.42 (C-6). 135.43 (C-2). 133.48 (C-10). 
129.07 (C-8). 128.70 (C-9). 126.91 (C-4). 126.08 (C-3). 
125.78 (C-l). 118.76 (C-7). 105.35 (C-5). 72.40 (COO 
CH2). 70.38. 70.32. 70.28. 70.06. 68.80. 63.79. 61.45 (11x 
OCHQ. 55.09 (OCHs). 45.12 (QHCHS). 18.36 (CHQH3) 
ppm. 
Reaction of Naproxen Acid Chloride with Monoprotected 
Tetraethylene Glycol 
An alternative approach for the preparation of the 
naproxen-polyethylene glycol prodrugs is also shown in 
Scheme 1 below. This method required the selective pro 
tection of one of the two PEG-hydroxyl groups as a silyl 
derivative. Subsequent acylation and deprotection led to the 
expected prodrug. according to the description below. 
To a solution of mono(t-butyldiphenylsi1yl) tetraethylene 
glycol (1 mmol) in 10 mL of dry dichloromethane and 113 
uL of pyridine at 0° C. was added naproxen acid chloride 
(1.1mmol). The resulting mixture was then stirred at room 
temperature overnight. washed successively with sodium 
bicarbonate solution. water. brine and ?nally dried over 
Na2SO4. The crude product was puri?ed by chromatography 
(hexanezethyl acetate. 3:1) to yield 620 mg (96.5%) of the 
monoprotected pure ester of naproxen and telraethylene 
glycol 3. 1H NMR (CDCL3) B 1.05 (s. 9H. t-Bu). 1.58 (d. 
3H. CHCHB). 3.51-3.81 (m. 14H. OCH3). 3.85 (q. 1H. C 
HCHS). 3.87 (s. 3H. OCHQ). 4.20 (m. 2H. COOCH3). 
7.07-7.72 (m. 6H. aromatic) ppm 
Deprotection of Compound 3 (Scheme 1 below). 
To a solution of 620 mg of3 inTl-IF (10 mL) at 0° C. was 
added glacial acetic acid (0.3 mL) and a 1M solution of 
tetrabutylammonium ?uoride in THF (2.5 mL). The reaction 
mixture was stirred at room temperature overnight. diluted 
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with diethyl ether (20 mL) and washed successively with 
ammonium chloride solution. water. and brine. Drying over 
Na2SO4 and solvent evaporation a?orded a colorless oil. 
which was puri?ed by column chromatography 
(benzenezacetone. (4:1). The monoester of naproxen and 
tetraethylene glycol 1c was obtained as a colorless oil (360 
mg. 92.3% yield). 
Reaction of Flurbiprofen Acid Chloride with Monoprotected 
Trimethylene Glycol (Scheme 2 below) 
Flurbiprofen acid chloride (434 mg. 1.65 mmol) was 
added to a solution of mono('t-butyldiphenylsilyl) 
trimethylene glycol (1.5 mmol) and 170 pL of pyridine in 15 
mL of dry dichloromethane at 0° C. The resulting mixture 
was then stirred at room temperature overnight washed 
successively with sodium bicarbonate solution. water. brine 
and ?nally dried over Na2SO4. The residue was puri?ed by 
column chromatography (hexanezethyl acetate. 6:1 up to 
4:1) yielding 774 mg (82%) of pure 4. 1H NMR(CDCLQ) [5 
1.03 (s. 9H. 't-Bu). 1.52 (d. 3H. CH3). 3.51—3.73 (m. 10H. 
OCH2). 3.82 (q. 1H. CHCHS). 4.25 (m. 2H. COOCHZ). 
7.11-7.70 (m. 8H. aromatic ppm). 
Deprotection of Compound 4. 
A 1M solution of tetrabutylammonium ?uoride in THF 
(3.1 mL) was added to an ice-cooled solution of 4 (774 mg. 
1.26 mmol) and glacial acetic acid (380 11L) in 10 mL of 
THF. After the mixture was stirred at room temperature 
overnight. diethyl ether (20 mL) was added and the solution 
washed with ammonium chloride solution. water and brine. 
The crude product was puri?ed by column chromatography 
(benzenezacetone. 9:1. up to 4:1) yielding 391 mg (82.4%) 
of the pure ester of ?urbiprofen and trimethylene glycol 5. 
1H NMR (CDCL3) [i 1.55 (d 3H. CH3). 2.40 (1H. OH). 
3.55-3.75 (m10H13. OCHQ). 3.80 (q. 1H. CHCH3). 4.27 (m. 
2H. COOCHZ). 7.1—7.55 (m. 8H. aromatic) ppm: 13C NMR 
(CDCL3) B 173.94 (C=O). 159.50 (d.J=248 Hz. 02). 
141.65 (C-l). 135.41 (C-4). 128.85 (C-6). 128.80. 128.41. 
127.62 (C-2'.3‘.4'). 128.80 (C-l'). 123.55 (C-5). 116.21 
(C-3). 72.46. 70.55. 70.31. 69.09. 64.07. 61.75 (6XCH2). 
44.81 (QHCH3). 18.52 (CH3) ppm. ‘ 
Prodrugs From the Reaction of Plurbiprofen Acid Chloride 
with Polyethylene Glycols (PEG). HO(CH2. CHZOR. n=4. 6 
(Scheme 2). 
To a solution of the appropriate polyethylene glycol (0.83 
mmol) in 10 mL of dry dichloromethane was added at room 
temperature 94 1.1L of pyridine followed by 221.9 mg (0.83 
mmol) of ?urbiprofen acid chloride. The reaction mixture 
was stirred at room temperature overnight. washed succes 
sively with sodium bicarbonate solution. water. brine and 
?nally dried over Na2SO4. In this one reaction. two prodrugs 
were obtained. which were easily separated as described 
below. 
Compounds 6a and 7a; Flurbiprofen 
The crude mixture (238 mg) was separated by chroma 
tography. The column bed was washed with benzenezac 
etone (9:1) up to benzenezacetone (411). Two fractions were 
collected: ?rst the diester of ?urbiprofen and tetraethylene 
glycol 7a (119 mg. 22% yield) followed by monoester 6a 
(105 mg. 30% yield), both as colorless oils. 7a 1H NMR 
(CDCL3) 13 1.55 (d. 6H. CH3). 3.52-3.73 (m. 12H. OCHZ). 
3.78 (q. 2H. CHCH3. 4.25 (m. 4H. COOCHZ). 7 .11-7.63 (m. 
16H. aromatic) ppm; 13C NMR (CDCL3) B 173.78 (C=O). 
159.51 (d. J=248 Hz. C-2). 141.69 (C-1). 135.36 (C-4). 
130.64 (C-6). 128.81. 128.35. 127.57 (C-2'. 3‘. 4'). 127.75 
(C-l'). 123.52 (C-5). 115.2 (C-3). 70.48. 70.44. 68.90. 63.99 
(8xCH2). 44.83 (QHCH3). 18.31 (CH3) ppm. 6a 1H NMR 
(CDCL3) [i 1.55 (d. 3H. CH3). 2.75 (1H. OH). 3.55-3.75 (m. 
14H. OCH2). 3.81 (q. 1H. CHCH3). 4.25 (m. 2H. COOCH2). 
5,681,964 
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7.10-7.55 (m. 8H. aromatic) ppm; 13(2 NMR (CDCL3) [3 
173.78 (C=O). 159.50 (d. J=248 Hz. C-2). 141.65 (C-l). 
135.31 (04). 130.59 (C-6). 128.76. 128.30. 127.52 (02'. 3'. 
4'). 127.70 (C-l'). 123.47 (C-5). 115.13 (C-3). 72.36. 70.46. 
70.37. 70.36. 70.15. 68.88. 63.96. 61.54 (8><CH2). 44.52 ( 
CHCH3). 18.13 (CHQH3) ppm. 
Compounds 6b and 7b; Flurbiprofen 
The crude oil (337 mg) was chromatographed with ben 
zene:acetone (9: 1) up to benzene: acetone (4:1). Two prod 
ucts were isolated; the diester of ?urbiprofen and hexaeth 
ylene glycol 7b (155 mg. 25.3% yield) and monoester 6b 
(163 mg. 38.5% yield) as colorless oils. 7b 1H NMR 
(CDCL3) [5 1.54 (d. 6H. CH3). 3.51-3.72 (m. 20H. OCHZ). 
3.78 (q. 2H. CHCHS). 4.25 (m. 4H. COOCHI). 7.12-7.52 
(m. 16H. aromatic) ppm; 13C NMR (CDCL3) B 173.84 
(C=O. 159.50 (d. 1:248 Hz. C-2). 141.71 (C-l). 135.40 
(C-4). 130.68 (C-6). 128.84. 128.37. 127.59 (C-2‘.3'.4'). 
127.78 (01‘). 123.52 (C-5). 115.22 (C-3). 70.51. 70.48. 
68.93. 64.03 (12><OCH3). 44.83 (QHCH3). 18.35 (CH 
CH3) ppm. 6b 1H NMR (CDCL3) {3 1.55 (d. 3H. CH3). 3.10 
(1H. OH). 3.54-3.74 (m. 22H. OCHZ). 3.81 (q. 1H. C 
HCH3). 4.26 (m. 2H. COOCH2). 7.12-7.55 (m. 8H. 
aromatic) ppm; 13C NMR (CDCL3) [3 173.66 (C=O). 
159.40 (d. J=248 Hz. 02). 141.57 (C-l). 135.21 (C-4). 
130.51 (C-6). 128.67. 128.21. 127.42 (C-2'. 3'. 4’). 127.58 
(C-1'). 13.38 (C-5). 115.06 (C-3). 72.36. 70.33. 70.27. 
70.03. 68.74. 63.89. 61.39 (12><CH2). 44.65 (QHCH3). 18.18 
((112113) ppm 
Synthesis of prodrugs from Triamcinolone Acetonide and 
Polyethylene Glycols (PEG). HO(CH2CH2O)nH. n=2. 3. 4 
Polyethylene glycols have been linked via a carbonate 
bond to triamcinolone acetonide as shown in Scheme 3 
below. The following procedure utilized the chloroformate 
of triamcinolone acetonide as an intermediate. 
Triamcinolone acetonide (1 mmol) was dissolved in 15 
mL of anhydrous dioxane and 5 mL of anhydrous tetrahy 
drofuran in a closed vial. The stirred mixture was cooled in 
an ice bath and anhydrous pyridine (80.9 p13) was added. 
then phosgene (8 mL of a 1.93M solution in toluene) was 
slowly added via a syringe. The vial was closed and the 
mixture was stirred at room temperature overnight. The 
progress of the reaction was monitored by TLC. using 
benzenezacetone (4:1) as a solvent system. After 16b the 
reaction was complete and the solvents were evaporated 
under vacuum on a rotary evaporator. The crude and 
unstable chloroformate of triamcinolone acetonide was dis 
solved in 15 mL of anhydrous dioxane and 5 mL of 
anhydrous tetrahydrofuran. and to this mixture 80.9 uL of 
anhydrous pyridine was added. followed by the appropriate 
polyethylene glycol (1 mmol). The mixture was stirred at 
room temperature overnight. concentrated on a rotary 
evaporator under vacuum and the residue redissolved in 
CHZCIZ (30 mL). The solution was washed with water. brine 
and ?nally dried over anhydrous Na2SO4 and evaporated to 
atford a solid foam. 
(a) Compound 8a. 
The crude reaction residue (512 mg) was puri?ed by 
chromatography. The column bed was washed with benze 
ne:acetone (6:1) up to benzenezacetone (2:1). yielding 131.4 
mg (23.2%) of the pure carbonate linked ester of triamci 
nolone acetonide and diethylene glycol 3a. ‘H NMR 
(CDCx3) B 0.94 (s. 3H. C-18). 1.21 (s. 3H. C-19). 1.41. 1.55 
(2s. 6H. isopropylidene). 3.05 (m. 1H. OH). 3.40 (m. 1H. 
C-16). 3.58-3.85 (m. 6H. OCH;). 4.30-4.40 (In. 2H. 
C00CH2). 4.41-4.46 (m. 1H. C-11). 4.82. 5.05 (2d. 2H. 
C-21). 5.01 (d. 1H. OH). 6.15 (s. 1H. G4). 6.36 (d. 1H. C-2). 
732 (d. 1H. C-l) ppm; 13c m (CDCL3) [3 203.51 
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(C=O.C-20). 186.67 (C=O. 03). 166.43 (C-5). 155.05 
(OCOO). 152.55 (C-l). 129.54 (C-2). 124.91 (C-4). 111.52 
(C. isopropylidene). 100.15 (d. C-9). 97.44 (C-17). 81.80 
(C-16). 71.62 (C-ll). 72.31 (C-21). 70.33. 68.90. 67.38. 
61.60 (4X0CH2). 48.19 (d. C-10). 45.58 (C-13). 42.97 
(014). 36.71 (C-15). 33.59 (C-12). 33.15 (d. C-8). 30.84 
(C-6). 27.51 (C-7). 26.40. 25.68 (2><CH3. isopropylidene). 
22.87 (d, C-19). 16.21 (C-18) ppm. 
Compound 8b; Triamcinolone acetonide 
The crude product (542 mg) was chromatographed with 
benzenezacetone (3:1) up to benzenezacetone (2:1) to yield 
138.4 mg (22.7%) of the carbonate linked ester of triamci 
nolone acetonide and trimethylene glycol 8b as a white 
solid. 1H NMR (CDCL3) [5 0.94 (s. 3H. C-18). 1.21 (s. 3H. 
C-19). 1.42. 1.55 (2s. 6H. isopropylidene). 3.05 (m. 1H. 
OH). 3.47 (m. 1H. C-16). 3.58-3.80 (m. 10H. OCHZ). 
4.25-4.34 (m. 1H. C-ll). 4.36-4.51 (m. 2H. COOCH2). 
4.84. 5.01 (2d. 2H. C-21). 5.02 (d. 1H. OH). 6.13 (s. 1H. 
C-4). 6.34 (d.1H. 02). 7.28 (d. 1H. C-1) ppm; 13C NMR 
(CDCL3) B 203.41 (C=O. C-20). 186.57 (C=O. C-3). 
166.24 (C-5). 154.90 (OCOO). 152.40 (C-l). 129.60 (C-2). 
125.02 (C-4). 111.50 (C. isopropylidene). 99.64 (d. C-9). 
97.41 (C-17). 81.77 (C-16. 71.71 (d. C-11). 72.20 (C-21). 
70.61. 70.33. 70.22. 68.89. 67.39. 61.59 (6xOCH2). 48.20 
(d. C-10). 45.52 (C-13). 43.02 (C-14). 36.63 (C-15). 33.60 
(C-12). 33.26 ((1. C-8). 30.86 (C-6). 27.52 (C-7). 26.40. 
25.64 (2XCH3. isopropylidene). 22.88 (d. C-19). 16.17 
(C-18) ppm. 
Compound 8c; Triamcinolone acetonide 
The yellow solid product (547 mg) was puri?ed by 
chromatography. The column bed was washed with benze 
nezacetone (2:1) yielding 190 mg (29%) of the pure carbon 
ate linked ester of triarncinolone acetonide and tetraethylene 
glycol 8c. 1H NMR (CDCL3) B 0.95 (s. 3H. C-18). 1.20 (s. 
3H. C-19). 1.42. 1.56 (2s. 6H. isopropylidene). 3.25 (s. 1H. 
OH). 3.40-3.55 (m. 1H. C-l6). 3.60-3.85 (m. 14H. OCH2). 
4.28-4.35 (m. 1H. C-ll). 4.35-4.50 (m.2H. COOCH2). 4.92 
(s. 2H. C-21). 5.01 (d. 1H. OH). 6.16 (s. G4). 6.37 (d. 1H. 
02). 7.25 (d. 1H. 01) ppm; 13c m (CDCLQ) [5 203.63 
(C=O. 020). 186.42 (C=O. C-3). 165.79 (05). 155.03 
(OCOO). 152.01 (C-l). 129.79 (C-2). 125.17 (C-4). 111.54 
(C. isopropylidene). 100.09 (d. C-9). 97.53 (C-17). 81.89 
(C-16). 71.76 (d. C-11). 72.54. 70.66. 70.61. 70.35. 70.22. 
68.96. 67.81. 61.17 (8XOX1'I2). 48.15 (d. C-lO). 45.66 
(GB). 43.04 (C- 14). 36.81 (C-15). 33.69 (C-12). 33.23 (d. 
C-8). 30.87 (C-6). 27.55 (C-7). 26.46. 25.73 (2><CH3 
isopropylidene). 22.97 (d. C-19). 16.30 (C-18) ppm. 
Reaction of triamcinolone acetonide with the chloroformate 
of monoprotected tetraethylene glycol (Scheme 3 below). 
To a solution of mono(t-butyldiphenylsilylhetraethylene 
glycol chloroformate (1 mmol) in 10 mL of a mixture of dry 
acetonitn'le:dioxaneztetrahydrofuran (1:1:1) at 0° C. was 
added 113 pl. of anhydrous pyridine and 1 mmol of triarn 
cinolone acetonide. The resulting mixture was stirred at 
room temperature overnight. then evaporated to dryness. 
dissolved in dichloromethane and washed successively with 
water. brine. and ?nally dried over Na2SO4. The crude 
product was puri?ed by chromatography (benzenezacetone. 
9:1) to yield 402.5 mg (41%) of pure 9. 1H NMR (CDCl3)5 
0.92 (s. 3H. C-18). 1.02 (s. 9H. t-Bu). 1.18 (s. 3H. C-19). 
1.40. 1.54 (25. 6H. isopropylidene). 3.55-3.60 (m. 1H. 
C-16). 3.60-3.75 (m. 12H. OCHZ). 3.75-3.82 (m. 2H. 
CH2OSi). 4.25-4.35 (m. 2H. C-11). 4.79. 4.98 (2d. 2H. 
C-21). 6.10 (s. 1H. G4). 6.32 (d. 1H. C-2). 7.15 (d. 1H. 
C-l). 7.30-7.70 (m. 6H. aromatic) ppm. 
Deprotection of Compound 9. 
To a solution of 402.5 mg of 9 in THF (8 mL) was added 
at 0° C. glacial acetic acid (134 pL) and a 1M solution of 
5,681,964 
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tetrabutylammonium ?uoride in THF (1.2 mL). The reaction 
mixture was stirred at room temperature overnight. then 
evaporated to dryness. redissolved in ethyl acetate (20 mL) 
and washed successively with ammonium chloride solution. 
water and brine. Drying over P182804 and solvent evapora 
tion left a yellow solid product. which was puri?ed by 
column chromatography (benzenezacetone. 2:1). The 
triamcinolone-tetraethylene glycol prodrug 8c was obtained 
as a white powder (191 mg. 64.7% yield). 
Synthesis of prodrugs from 5B-pregnane-3u.17ct.2l-triol 
20-0ne (THS) and polyethylene glycols (PEG). 
H0(CH2CH2O)H n=2. 4. 
Polyethylene glycols have been linked to THS via a 
carbonate moiety as shown in Scheme 4 below. This 
approach requires the selective protection of one of the two 
hydroxyl groups of the PEG as a silyl derivative and allows 
one to obtain and easily separate three protected prodrugs in 
one reaction. Subsequent separation and deprotection of the 
above mixture of products led to the expected prodrugs: the 
C-30L. C-21 bicarbonate ester of THS with the appropriate 
PEG. the C-3o. monocarbonate ester of THS with the 
appropriate PEG. the C-21 monocarbonate ester of THS and 
the appropriate PEG. The following example describes the 
classical procedure for the preparation of these prodrugs. 
An appropriate mono(t-butyldiphenylsilyl)polyethylene 
glycol (2 mmol) was dissolved in 18 mL of anhydrous 
tetrahydrofuran. The stirred solution was cooled in an ice 
bath and anhydrous pyridine (161.8 pl.) was addal and then 
phosgene (16 mL of a 1.93M solution in toluene) was slowly 
added via a syringe. The vial was closed and the mixture was 
stirred overnight at room temperature. The progress of the 
reaction was monitored by TLC using hexane:ethyl acetate 
(9:1) as a solvent system. After 18 hours the reaction was 
completed and the solvents were evaporated under vacuum 
on a rotary evaporator. The crude and unstable chlorofor 
mate was redissolved in an acetonitrile: tetrahydrofuran 
(1:1) mixture (20 mL) and to this solution 162 uL of 
anhydrous pyridine was added. followed by the trishydrox 
ysteroid (1 mmol). The mixture was stirred overnight at 
room temperature. concentrated on a rotary evaporator and 
redissolved in ethyl acetate (80 mL). The solution was 
washed with water. brine. dried over anhydrous NazSO4. 
evaporated to an oil and the reaction products separated: 
Compounds 10. 11 and 12 
The crude oil (995 mg) was separated by chromatography. 
The column bed was washed with benzenezacetone (40:) up 
to benzene:acetone (4:1). to give three fractions. The ?rst 
fraction contained the less polar C-3ot. C-21-bicarbonate 
ester of THS and monoprotected diethylene glycol 10 (403.6 
mg. 37%). the second fraction contained the more polar 
C-3 tut-carbonate ester of THS and monoprotected diethylene 
glycol 11 (106.5 mg. 14.8%). the third fraction contained the 
most polar C-2l carbonate ester of THS and monoprotected 
diethylene glycol 12 (166.2 mg. 23.1%). all compounds 
were obtained as white solid foams. 10 1H NMR (CDCl3) 5 
0.68 (s. 3H. C-18). 0.96 (s. 3H. C-l9). 1.1 (s. 18H. t-Bu). 
2.35 (s. 1H. C-170t0?). 3.6-3.8 (rn. 8H. OCH2). 3.8-3.9 (m. 
4H. CHZOSi). 4.23-4.38 (m. 4H. OCOOCHZ). 4.57-4.69 
(m. 1H. C-3). 4.87. 5.17 (2d. 2H. C-21). 7.37-7.79 (m. 20H. 
aromatic) ppm. 11 1H NMR (CDCl;) 5 0.63 (s. 1H. C-l8). 
0.93 (s. 3H. C-19). 1.05 (s. 9H. t-Bu). 2.2 (s. 1H. C-17otO 
H). 2.30-2.45 (111. PH. C-21-OH). 3.55-3.78 (m. 4H. 
OCH;). 3.80-3.84 (m. 2H. CH2OSi). 4.19-4.28 (m. 2H. 
OCOOCHQ). 4.25. 4.67 (2d. 2H. C-21). 4.52-4.61 (m. 1H. 
C-3). 7.3s_7.73 (m. 10H. aromatic) ppm. 12 ‘H NMR 
(CDCl3) 5 0.63 (s. 3H. C-18). 0.96 (s. 3H. C-19). 1.04 (s. 
9H. t-Bu). 2.08 (s. 1H. C-l7-Om. 2.95 (s. 1H. 03110.11). 
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3.55-3.65. 3.70-3.87 (m. 4H. OCH;). 3.65-3.70 (m. 1H. 
C-3). 3.88-4.05 (m. 2H. CH2OSi). 4.25-4.35 (m. 2H. 
OCOOCH2). 4.81. 5.15 (2d. 2H. C-21). 7.32-7.72 (m. 10H. 
aromatic) ppm. 
Compounds 13. 14 and 15; THS 
The oily residue (911 mg) was separated by chromatog 
raphy. The column was washed with benzene :acetone (15:1) 
up to benzenezacetone (6:1). Three fractions were collected: 
the ?rst fraction contained the less polar C-30t.C-21 
bicarbonate ester of THS and monoprotected tetraethylene 
glycol 13 (202.2 mg. 16.2% yield). the second fraction 
contained the C-3ot-monocarbonate ester of THS and mono 
protected tetraethylene glycol 14 (228.6 mg. 28.1% yield) 
and ?nally the third fraction contained the C-tetraethylene 
glycol 14 (228.6 mg. 28.1% yield) and ?nally the third 
fraction contained the C-tetraethylene glycol 14 (228.6 mg. 
28.1% yield) and ?nally the third fraction contained the 
C-21-carbonate ester of THS and monoprotected tetraethyl 
ene glycol 15 (222 mg. 27.4%). all compounds were obtain 
as colorless oils. 13 1H NMR (CDCL3) [5 0.62 (s. 3H. C-19). 
0.93 (s. 3H.C-19). 1.02 (s. 18H. t-Bu). 2.01 (s. 1H. C-170t0 
m. 3.55-3.76 (m. 24H. ()CHz). 3.78-4.02 (m. 4H. 
CH2OSi). 4.22-4.34 (m. 4H. OCOOCHZ). 4.50-4.65 (m. 
1H. 03). 4.82. 5.13 (d. 2H. C-21).7.35-7.74 (m. 20H. 
aromatic) ppm. 14 1H NMR (CDCL3) B 0.61 (s. 3H. G8). 
0.93 (s. 3H. C-19). 1.02 (s. 9H. t-Bu). 2.08 (s. 1H. 017010 
E. 3.09 (t. 1H. C-21-Ow. 3.58-3.75 (m. 12H.0CH2). 
3.77-4.83 (m. 2H. CH2OSi). 4.23-4.26 (m. 2H. 
OCOOCH2). 4.30. 4.68 (2d. 2H. C-21). 4.5-4.65 (m. 111. 
C-3). 7.35-7.72 (m. 10H. aromatic) ppm. 15 lH. aromatic) 
ppm. 15 1H NMR (CDCL3) [3 0.63 (s, 3H. C-18). 0.92 (s. 
3H. C-19). 1.02 (s. 9H. t-Bu). 2.21 (s. 1H. C-l7otOH). 
3.55-3.58 (m. 2H. CH-3ot-O?). 3.60-3.78 (m. 12H. OCH2). 
3.79-4.03 (m. 2H. CH2). 3.79-4.03 (m. 2H. CHZOSi). 
4.27-4.35 (m. 2H. OCOOCH2). 4.82-5.14 (2><d. 2H. C-21 ). 
7.34-7.74 (m. 10H aromatic) ppm. 
Deprotection of THS-PEG (n=2)-silyl Derivatives (Scheme 
4 below) 
Deprotection of Compound 10 
A M solution of tetrabutylammonium ?uoride in THF (2 
mL) was added to an ice-cold solution of 10 (403 .6 mg. 0.37 
mmol) in glacial acetic acid (222 pl.) and tetrahydrofuran 
(15 mL). The mixture was stirred overnight at room 
temperature. concentrated. redissolved in ethyl acetate and 
washed with ammonium chloride solution. water. brine and 
?nally dried over Na2SO4. The product was puri?ed by 
column chromatography (benzenezacetone. 6:1 up to 
benzene:acetone. 4:1) yielding 175 mg (77%) of the G311. 
C-21 bicarbonate ester of THS and diethylene glycol. 16. as 
a white stable foam. 1H NMR (CDCL3) [50.63 (s. 3H. C-18). 
0.96 (s. 3H. C-19). 2.78-2.88 and 3.01-3.13 (2m. 2H. CHzO 
H). 3.28 (s. 1H. C-170t0H). 3.62-3.81 (m. 12H. OCHZ). 
4.25—4.28 (m. 2H. C-3ot-OCOOCH2). 4.29-4.38 (m. 2H. 
C-21-OCOOCH2). 4.51-4.65 (m. 1H. C-3). 4.85. 5.17 (2d. 
2H. C-21) ppm; 13C NMR (CDCL3) B 205.54 (C=O. C-20). 
154.80 (C-21-OQOO). 154.40 (C-3otOQOO). 89.82 (C-17). 
78.23 (C-30LOCO0). 72.40 (C-21-OCOOQH2). 72.27 
(C-30tOCOOCH2. 70.71 (c-21-ocoo). 68.73 
(C-30tOCOOCH2CH2). 68.75 (C-21-OCOOCH2CH2). 
67.10 (C-21-OCO0CH2CH20QH2CH20H). 66.41 
(C-3a0C00CH2CH20CH2CH2OH). 61.43 
2><CH2CH2OH). 50.90 (C-14). 48.36 (C-13. 41.57 (C-5). 
39.80 (C-9). 35.63 (C-8). 34.72 (C-2). 34.54 (C-1). 34.37 
(C-lO). 31.87 (C-4). 30.33. 26.28 (C- 16.C— 12). 26.27 (C-6. 
C-7). 23.48 (C-15). 23.03 (C-19). 20.32 (C-ll). 14.37 
(C-18) ppm. 
5 1.681964 
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Deprotection of Compound 11. 
To a solution of 106.5 mg of 11 in tetrahydrofuran (10 
mL) at 0° C. was added glacial acetic acid (44 uL) and a 1M 
solution of tetrabutylarnmonium ?uoride in THF (395 pL). 
The reaction mixture was stirred at room temperature over 
night and after typical work-up. and separation by chroma 
tography (benzene:acetone. 9:1 up to benzenezacetone. 6:1) 
was obtained 55.2 mg (77.4% yield) of the C-3ot monocar 
bonate ester of THS and diethylene glycol. 17. as a white 
solid foam. 1H NMR (CDCL3) [i 0.62 (s. 3H. C-18). 0.95 (s. 
3H. C-19). 2.37-2.45 (m. 1H. CH2CH2OH). 2.55 (s. 1H. 
C-170LOH). 3.18 (t. 1H. C-2l-OH).3.57-3.78 (m. CH. 
OCHZ). 4.23-4.35 (m. 2H. C-3OLOCOOCH2). 4.30. 4.68 
(2><d. 2H. c-21). 4.54-4.60 (m. 1H. CH-CaOOO) ppm; 13c 
NMR (CDCL3) 5214.43 (C=O. C-20). 154.60 (C-3otO 
Q00). 89.22 (C- 17). 78.30 (C-30tOCOO). 72.31 
(C-30tOC00QH2). 68.91 (C-3Ot-OCOOCH2QH2) 67.38 
(C-21-OH). 66.51 (C-3otOCOOCH2CH2OCH2CH2OH). 
61.65 (2><CH2QH20H). 50.91 (C-14). 48.83 (C-13). 41.69 
(C-5). 40.03 (C-9). 35.7 (C-8). 34.85(C-2). 34.58 (C-1). 
34.50 (C-10). 31.98 (C-4). 30.47. 26.79 (C-l6. C-12). 26.40 
(C-6. C-7). 23.72 (C-15). 23.12 (019). 20.29 (C-ll. 15.06 
(C-18) ppm. 
Deprotection of Compound 12 
To a solution of 166.2 mg of 12 in THF (12 mL) at 0° C. 
was added glacial acetic acid (68 pL). followed by a 1M 
solution of tetrabutylammonium ?uoride in THF (61 mL). 
After overnight stirring at room temperature and classical 
work-up with ?nal separation by chromatography 
(benzenezacetone. 4:1 up to benzene:acetone. 2:1) was 
obtained 95.1 mg (83.9% yield) of the C-21 monocarbonate 
ester of THS and diethylene glycol. 18. as a white solid 
foam. 1H NMR (CDCL3) 13 0.61 (s. 3H. C-l8). 0.90 (s. 3H. 
C-19). 2.48 (s. 1H. C-17ctOH). 2.95-3.10 (m. 1H. 
CHZCHZOH). 3.46 (s. 1H. C-3otOl-I_). 3.53-3.80 (m. 7H. 
OCH2 and C_I;I_-30!OH). 4.27-4.42 (m. 2H. C-21-OCOOC 
112). 4.82. 5.18 (2><d. 2H. 021) ppm. 13c mm (01x13) {5 
205.72 (C=O). 154.91 (C-21-OCOO). 89.93 (017). 72.49 
(C-2l-OCOOCH2). 71.60 (C-30t0l-l). 70.84 ( 
Q-ZI-OCOO). 68.73 (C-21-OCOOCH2CH2). 67.19 (C-21 
OCOOCH2OCH2CH2CGH2OH). 61.51 (CH2QH2OH). 
51.05 (C-14). 48.48 (013). 41.87 (C-5). 39.96 (C-9). 35.78 
(C-8). 36.03 (C-2). 35.23 (C-1). 34.55 (C-lO). 30.46 (C-4). 
30.44. 30.31 (C-16. C-12). 26.97. 26.49 (C-6. C-7). 23.56 
(C-15). 23.20 (C-19. 20.39 (C-ll). 14.48 (C-18) ppm. 
Deprotection of THS-PEG(n=4)-Silyl Derivatives (Scheme 
4 below) 
Deprotection of Compound 13 
To a solution of 202 mg of 13 in THF (15 mL) at 0° C. 
was added glacial acetic acid (92 uL) and then a [M solution 
of tetrabutylammonium ?uoride in THF (870 1.1L). After 
overnight reaction at room temperature. extraction. as 
described above. and separation by column chromatography 
with benzene:acetone (1:1). the C-30t. C-21 bicarbonate 
ester of THS and tetraethylene glycol 19 (103.8 mg. 82% 
yield). was obtained as a colorless oil. 1H NMR (CDCL3) B 
0.68 (s. 3H. C-18. 0.95 (s. 3H. C-l9). 2.53 (s. 1H. C-l7ot0 
H). 2.55 (m. 2H. CH2CH2OH). 3.58-3.82 (m. 28H. 0CH2). 
4.23-4.30 (m. 2H. C-3t1OCOOCH2). 4.30-4.37 (m. 2H. 
C-21-OCOOC?2). 4.52-4.63 (m. 1H. CH-3orOCOO). 5.01. 
5.18 (2d. 2H. 021) ppm; 13c NMR (CDCL3) [5 204.73 
(C=O. C-20. 154.82 (C-21-OCO0). 154.50 (C-3ot0 
Q00). 90.13 (C-l7). 78.10 (Q-3otOCOO). 72.46 (C-21 
OCOOQH2). 72.44 (C-3ot0COOQH2). 70.66 
(Q-21=OCOO). 70.64. 70.56. 70.50. 70.39. 70.35. 70.31. 
68.94. 68.92 (10><OCH2). 67.43 (C-ZI-OCOO-PEG-O 
CHZCHZOH). 66.62 (C-30tOCOO-PEG-OQH2CH2OH) . 
20 
25 
30 
35 
50 
55 
65 
18 
61.74 (ZXCHZQHZOH). 51.17 (C-14). 48.55 (C-13). 41.70 
(C-5). 40.05 (C-9). 35.75 (C-8). 34.94 (C-2). 34.88 (C-1). 
34.50 (C-10). 31.99 (C-4). 30.56. 26.80 (C-16. C-12). 26.40 
(C-6. C-7). 23.59 (C-15). 23.12 (C-l9. 20.41 (C-ll). 14.65 
(018 ppm. 
Deprotection of Compound 14 
To a solution of 228.6 mg of 14 in THF (15 mL) at 0° C. 
was added glacial acetic acid (75 1.1L) and then a 1M solution 
of tetrabutylammonium ?uoride in THF (690 uL). Accord 
ing to the procedure in (a) above. by using benzene :acetone 
(2:1) for chromatographic separation. the C-3a 
monocarbonate ester of THS and tetraethylene glycol 20 
(112.8 mg. 79.8% yield). was obtained as a colorless oil. 1H 
NMR (CDCL3) B 0.63 (s. BK. 018). 0.95 (s. 3H. C-19). 
2.30 (s. 1H. 01701011). 2.53-2.60 (m. 1H. CHZCHQOH). 
3.11 (t. 1H. C-21-O?). 3.62-3.81 (m. 14H. OCHZ). 
4.23-4.30 (m. 2H. C-3otOCOOCH2). 4.30. 4.68 (2><d. 211. 
021). 4.52-4.62 (m. 1H. CH-3ctOCOO) ppm; 130 NMR 
(CDCL3) B 212.32 (C=O. C-20). 154.50 (C-3otOQOO). 
89.27 (C-17). 78.12 (Q-3otOCOO). 72.45 (C-3otOCOO 
CH2). 70.62. 70.55. 70.48. 70.33. 68.94 (5xOCH2). 67.41 
(C-21-OH). 66.62 (QH2CH2OH). 61.74 (CHZCHZOH). 
50.97 (C-14). 48.90 (GB). 41.68 (C-5). 40.07 (C-9). 35.73 
(C-8). 34.86 (C-2). 34.64 (C- 1). 34.50 (C-lO). 31.97 (C-4). 
30.49. 26.77 (C-l6. C-12). 26.39 (C-6. C-7). 23.72 (C-15). 
23.11 (C-19). 20.28 (C-ll). 15.10 (C-18) ppm. 
Deprotection of Compound 15 
Using the same molar ratio of glacial acetic acid to 
tetrabutylammonium ?uoride as was described in procedure 
(b) above. 222 mg of 15 atforded the C-2 l-monocarbonate 
ester of THS and tetraethylene glycol 21 (113 mg. 80.2% 
yield). as a white solid foam. 1H NMR (CDCL3) [5 0.62 (s. 
3H. C-18). 0.92 (s. 3H. C-19). 2.28 (s. 1H. C-170LOH). 
2.80-2.90 (m. 1H. CH2CH2OH). 3.40 (s. 1H. CH-30LOH). 
3.55-3.80 (m. 15H. OCH2 and Cli-3otOH). 4.25-4.40 (m. 
2H. C-21-OCOOCH2). 4.81. 5.17 (2><d. 2H. 021) ppm; 13c 
NMR (CDCL3) [5 205.65 (C=0. 020). 154.81 (C-21-O 
COO). 89.90 (C-17). 72.47 (C-ZI-OCOOCHZ). 71.58 
(C-30tOH). 70.79 (Q-21-OCOO). 70.58. 70.41. 70.40. 
70.31. 68.85 (SXOCH2). 67.20 (OCHZCHQOH). 61.52 (CH2 
QHZOH). 51.02 (C-14). 48.30 .(C-13). 41.50 (C-5). 40.20 
(C-9). 36.01 (C-2). 35.76 (C-8) 34.25 (C-1). 34.48 (010). 
34.45 (C-4). 30.40. 30.29 (G16. G12). 26.92 (C-6). 26.48 
(C-7). 23.58 (C-15). 23.20 (C-19). 20.40 (C-ll). 14.52 
(C-18) ppm. 
Synthesis Example of Prodrugs from Gancyclovir and dieth 
ylene glycol (Numbers refer to synthesis scheme where 
appropriate). 
185 mg of N-protected gancyclovir (1) was dissolved in 
a mixture of dry acetonitrile (2 mL) and dry THF (2 mL) 
followed by addition of anhydrous pyridine (97 pL). The 
mixture was cooled in an ice-bath and a solution of 428 mg 
of the chloroformate (2) in 2 mL of THF was slowly added. 
The resulting mixture was stirred at room temperature for 
16 h. and the solvents were evaporated. The oily residue was 
redissolved in 10 mL of chloroform. washed with water 
(2X). brine and dried over sodium sulfate. The residue after 
solvent evaporation was chromatographed on silicagel. Elu 
tion with benzeneacetone yielded 200 mg of dicarbonate (3). 
The structure of this intermediate was con?rmed by 1H and 
13C NMR spectroscopy. 
53 mg of (3) was dissolved in 1.5 mL of THF and 200 pL 
of commercial tetrabutyl ammonium ?uoride in TI-[F was 
added. The resulting solution was stirred at 40° C. overnight. 
evaporated to dryness and redissolved in 3 mLof 80% acetic 
acid. The mixture was heated at 50° C. for 4 h and evapo 
rated under vacuum. The residue was puri?ed by column 
5,681,964 
19 20 
chromatography on silicagel to give 14 mg of prodrug (4). 40 mg of DDI (dideoxyinosine) was suspended in 2 mL 
1H-N'IVIRGOO MHz. CD3OD) 5 3.45(ms4H). 3.58(m.8H). of dry acetonitrile and 60 mg of carbonyldiimidazole was 
4.00-4.20(m.9H). 5.45(s.2H).7.75(s.1H), ‘3C-NMR(75.429 added. The resulting suspension was stirred at room tem 
MHz. CDSOD) 5 62.1. 67.5. 68.4. 69.8. 73.1. 73 .6(6>< perature for 3 h and to the resulting homogenous solution a 
C1120). 75.9(CHO). 117.6(C-5), 153.3(C-4). 155.6(C-2). 5 monoproteded diethylene glycol (5) was added. The mix 
l56.3(OCOO)_ l59.4(C-6)pprn. ture was then stirred at 90° C. for 36 h. The residue obtained 
Gancyclovir Synthesis Scheme after solvent evaporation was chromatographed on silicagel 
sfmm ancicloviranddieth lene leol 
e e j: 
H ° H ‘’ a)’ 
Ganciclovir 
o 
H 
N 1J1» MMTHN\N N 0 
RN JI N> I \ MMT'O > 
MMr-ms x N N > O 
nmso/\/ 0\/\ ocoo Dms—o/\/ °\/\ occo 
o 
nmseo/\/ O\/\ ocoo 
3 
l/l. Bu‘NF/I'HF BllaNF/I'HF 
2. AcOH 2. AcOH 
o I o 
H N H N Ii» IE» H2 N N H2 N N 
4 
MMT = monometlnxytrityl 
DPTBS = diphenyl-t-butylsilyl 
65 with chloroform-methanol solvent system to yield 45 mg of 
Synthesis Example of Prodrugs from DDI and diethylene (6). The carbonate (6) was dissolved in 1 mL of THF and 
glycol 150 pL of tetrabutylammonium ?uon'de solution was added 
5,681,964 
21 22 
followed by 150 pL of acetic acid. The reaction mixture was 
stirred at room temperature for 24 h. and the product was 
puri?ed by preparative thin-layer chromatography to yield 
12 mg of carbonate (7). ‘H-NMRGOO MHz, CDC13) 5 
2.20(m.2H), 2.55(m42H). 3.65-4.5(Im13H), 6.30(t.1H). 8.18 5 
(SJH). 8.22(s.1H). 13C-NMR(75.429 MHZ. CDCl3) 6 25.8 
(03‘). 32.7(0-2'). 61.3. 67.4. 67.8. 68.6. 72.8 (SXCHZO). 
78.5(C-4'). 85.0(C-1'). 125.0(C-5). 146.6(C-2). 148.2(C-4). 
155.0(OCOO). 158.3(C-6) ppm 
DDI Synthesis Scheme 
Prodru from DDI and dieth lens 1 col 
5 
O 
A 6 AcOH 
DDI 
O 
H\N N 
\ 
0 K 1 N) 
N 
0 
H 
° MO “ HT PIA-N I‘) 
KEEN‘) 1_\/ % lg!“ N 
HOKN N 

5,681,964 
25 26 
-continued 
SCHEME 3 
CHZOCCXXCHzCHZOW 8c 
o 
- 0 
8a, 11 = 2 
8b, 11 = 3 
8c, 11 = 4 
'I?amcimlone Acemnide + PEG 
SCHEME 4 
0 
cnzon c5201: 
" OH l-Bu(Ph);Si0(Cl-I;CH;O),,COCI ' ' 0H 
no’ no" 
H H 
CHZOR ' " 
65 
Table 1 below shows examples of the half-life and solu 
bility several of the compounds of the invention. 


